Frequent Links
Acorda Therapeutics
Acorda Therapeutics | |
Public | |
Traded as | NASDAQ: ACOR FWB: CDG |
Industry |
Health care Biotechnology |
Founded | 1995[1] |
Founder | Ron Cohen |
Headquarters | Ardsley, New York, United States |
Key people |
Ron Cohen Andrew R. Blight |
Products |
Zanaflex Ampyra Qutenza |
Revenue | 11px US$292.2 Million (FY 2011)[2] |
11px US$35.1 Million (FY 2011)[2] | |
#redirect Template:If affirmed | 11px US$30.6 Million (FY 2011)[2] |
Total assets | 11px US$379.5 Million (FY 2011)[2] |
Total equity | 11px US$205.2 Million (FY 2011)[2] |
Number of employees | 328 (February, 2012) [2] |
Website | Acorda.com |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
Contents
History
23px | This section is empty. You can help by adding to it. (January 2010) |
Corporate governance
As of December 31, 2013[update], the members of the board of directors of Acorda Therapeutics were:[4] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.
Products
Products on the market
20px | This section requires expansion. (January 2010) |
Products under development
23px | This section is empty. You can help by adding to it. (January 2010) |
References
- ^ Acorda FAQ
- ^ a b c d e f "Acorda Therapeutics 2011 Annual Report - Form 10-K - February 28, 2012." (PDF). secdatabase.com. Retrieved May 16, 2012.
- ^ Acorda 2008 10-K Annual report
- ^ Acorda Therapeutics 2013 Annual Report
External links
Lua error in package.lua at line 80: module 'Module:Buffer' not found.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.